Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Inflammation
Published in: Journal of Inflammation 1/2016

Open Access 01-12-2016 | Review

Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review

Authors: Alessandro Sciarra, Alessandro Gentilucci, Stefano Salciccia, Federico Pierella, Flavio Del Bianco, Vincenzo Gentile, Ida Silvestri, Susanna Cattarino

Published in: Journal of Inflammation | Issue 1/2016

Login to get access

Abstract

Prostate is an immune-competent organ normally populated by inflammatory cells. Prostatic inflammation origin can be multi-factorial and there are some emerging evidences on its possible role as a factor involved in prostate cancer (PC) pathogenesis and progression.
This review critically analyzes the role of inflammation as a prognostic factor for progression and aggressiveness of PC. We verified the last 10 years literature data on the association between inflammation and PC aggressiveness, or PC response to therapies.
Several studies tried to correlate different inflammatory factors with the aggressiveness and metastatization of PC; all data sustain the role of inflammation in PC progression but they also produce confusion to identify a reliable clinical prognostic marker.
Data on patients submitted to radical prostatectomy (RP) showed that cases with marked intraprostatic tissue inflammation are associated with higher rate of biochemical progression; systemic inflammation markers appear to have a significant prognostic value.
Analyzing data on patients submitted to radiotherapy (RT) emerges a significant association between high neuthrophil to lymphocyte ratio (NLR) and decreased progression free survival and overall survival; also plateled to lymphocyte ratio (PLR) and C-reactive protein (CRP) have been proposed as significant prognostic factors for progression and overall survival.
In patients submitted to androgen deprivation therapy (ADT), inflammation may drive castration resistant PC (CRPC) development by activation of STAT3 in PC cells. NLR has been proposed as independent predictor of overall survival in CRPC submitted to chemotherapy.
Most of data are focused on markers related to systemic inflammation such as NLR and CRP, more than specifically to chronic prostatic inflammation. The suggestion is that these inflammatory parameters, also if not specific for prostatic inflammation and possibly influenced by several factors other than PC, can integrate with established prognostic factors.
Literature
1.
Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, Sciarra A, Montorsi F. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia. BJU int. 2013;112:432–41.CrossRefPubMed
2.
Bostwick DG, de la Roza G, Dundore P, Corica FA, Iczkowski KA. Intraepithelial and stromal lymphocites in the normal human prostate. Prostate. 2003;55:187–93.CrossRefPubMed
3.
4.
De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, Sciarra A, Tubaro A. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur urol. 2011;60(1):106–17.CrossRefPubMed
5.
6.
Sfanos KS, Hempel HA, De Marzo AM. The role of inflammation in prostate cancer. Adv exp med biol. 2014;816:153–81.CrossRefPubMed
7.
Caruso C, Balistreri CR, Candore G, et al. Polymorphisms of pro-inflammatory genes and prostate cancer risk: a pharmacogenomic approach. Cancer immunol immunother. 2009;58:1919–33.CrossRefPubMed
8.
Sciarra A, Di Silverio F, Salciccia S, Gomez AMA, Gentilucci A, Gentile V. Inflammation and chronic prostatic diseases: evidence for a link? Eur urol. 2007;52(4):964–72.CrossRefPubMed
9.
Sciarra A, Mariotti G, Salciccia S, Gomez AA, Monti S, Toscano V, Di Silverio F. Prostate growth and inflammation. J steroid biochem mol biol. 2008;108(3–5):254–60.CrossRefPubMed
10.
Klein EA, Silverman R. Inflammation, infection and prostate cancer. Curr opin urol. 2008;18:315–9.CrossRefPubMed
11.
12.
Naber K, Weidner W. Chronic prostatitis: an infectious disease? J antimicrob chemoter. 2000;46:157–61.CrossRef
13.
Sugar LM. Inflammation and prostate cancer. Can j urol. 2006;13 Suppl 1:46–7.PubMed
14.
Palapattu GS, Sutcliffe S, Bastain PJ, Platz EA. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis. 2004;26:1170–81.CrossRefPubMed
15.
Veeranki S. Role of inflammasones and their regulators in prostate cancer initiation, progression and metastasis. Cell mol biol lett. 2013;18(3):355–67.CrossRefPubMed
16.
Bills A, Freitas LL, Magna LA, Ferreira U. Inflammatory atrophy on prostate needle biopsies: is there topographic relationship to cancer? Int braz j urol. 2007;33:355–60. discussion 361–353.CrossRef
17.
Billis A, Magna LA. Inflammatory atrophy of the prostate. Prevalence and significance. Arch pathol lab med. 2003;127(7):840–4.PubMed
18.
Gurel B, Lucia MS, Thompson Jr IM, Goodman PJ, Tangen CM, Kristal AR, Parnes HL, Hoque A, Lippman SM, Sutcliffe S, Peskoe SB, Drake CG, Nelson WG, De Marzo AM, Platz EA. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer epidemiol biomarkers prev. 2014;23(5):847–56.CrossRefPubMedPubMedCentral
19.
Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J immunother cancer. 2014;2:14–8.CrossRefPubMedPubMedCentral
20.
Mc Ardle PA, Canna K, Mc Millan DC, Mc Micol AM, Campbell R, Underwood MA. The relatioship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. BRJ cancer. 2004;91(3):541–3.CrossRef
21.
Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010;464(7286):302–5.CrossRefPubMedPubMedCentral
22.
Davidson S, Ohlson AL, Andersson SO, Fall K, Meisner A, Fiorentino M. CD4 helper T-cells, CD8 cytotoxic cells, and FOXP3 (+) regulatory T cells with respect to lethal prostate cancer. Mod pathol. 2013;26(3):448–55.CrossRef
23.
Gannon PO, Alam Fhamy M, Begin LR, Djoukhadjian A, Filali-Mouhim A, Lapointe R. Presence of prostate cancer metastasis correlate with lower lymph node reactivity. Prostate. 2006;66(16):1710–20.CrossRefPubMed
24.
Yin X, Xiao Y, Li F, Siyong Q, Yin Z, Gao J. Prognostic role of neutrophil-to-limphocyte ratio in prostate cancer. Medicine. 2016;95:1–8.CrossRef
25.
26.
Kwon YS, Han CS, Yu JW, Kim S, Modi P, Davis R, Park JH, Lee P, Ha YS, Kim WJ. Neutrophil and lymphocyte counts as clinical markers for stratifying low-risk prostate cancer. Clin genitourinary cancer, 2016;14(1):1–8.
27.
Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat immun. 2010;11(10):889–96.CrossRef
28.
Lanciotti M, Masieri L, Raspollini MR, Minervini A, Mari A, Comito G. The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy. Biomed res int. 2014;48:67-98
29.
Fang LY, Izumi K, Lai KP, Liang L, Li L, Miyamoto H. Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor—mediated CCL4-STAT3 signaling. Cancer res. 2013;73(18):5633–46.CrossRefPubMed
30.
Salazar N, Castellan M, Shirodkar SS, Lokeshwar BL. Chemokines and chemokine receptors as promoters of prostate cancer growth and progression. Crit rev eukaryot gene expr. 2013;23(1):77–91.CrossRefPubMedPubMedCentral
31.
Maxwell PJ, Neisen J, Messenger J, Waugh DJ. Tumor derived CXC8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells. Oncotarget. 2014;5(13):4895–908.CrossRefPubMedPubMedCentral
32.
Chen G, Liang YX, Zhu JG, Fu X, Chen YF, Mo RJ. CC chemokine ligand 18 correlates with malignant progression of prostate cancer. Biomed res int. 2014;2014:230183.PubMedPubMedCentral
33.
Ellem SJ, Taylor RA, Furic L, Larsson O, Frydenberg M, Pook D. A pro-tumourigenic loop at the human prostate tumor interface orchestrated by oestrogen, CXCL12 and mastcell recruitment. J Pathol. 2014;234(1):86–98.CrossRefPubMed
34.
Tsaur I, Noack A, Makarevic J, Oppermann E, Waaga-Gasser AM, Gasser M. CCL2 chemokine as a potential biomarker for prostate cancer: a pilot study. Cancer res treat. 2015;47(2):306–12.CrossRefPubMed
35.
Agaarwal M, He C, Siddiqui J, Wei JT, Macoska JA. CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer. Prostate. 2013;73(6):573–81.CrossRef
36.
Torrealba N1, Rodríguez-Berriguete G2, Fraile B3, Olmedilla G4, Martínez-Onsurbe P5, Guil-Cid M6, Paniagua R7, Royuela M8. Expression of several cytokines in prostate cancer: correlation with clinical variables of patients. Relationship with biochemical progression of the malignance. Cytokine. 2016 Aug 12. S1043-4666 (16) 30455-0. doi: 10.​1016/​j.​cyto.​2016.​08.​008. [Epub ahead of print]
37.
Brown DA, Lindmark F, Stattin P, et al. Macrophage inhibitory cytokine 1:a new prognostic marker in prostate cancer. Clin cancer res. 2009;15:6658–64.CrossRefPubMedPubMedCentral
38.
Culig Z. Proinflammatory cytokine interleukin-6 in prostate carcinogenesis. Am j clin exp urol. 2014;2(3):231–8. Published online 2014 Oct 2.PubMedPubMedCentral
39.
Pencik J, Wiebringhaus R, Susani M, Culig Z, Kenner L. IL-6/STAT3/ARF: the guardians of senescence, cancer progression and metastasis in prostate cancer. Swiss med wkly. 2015;145:w14215. doi:10.​4414/​smw.​2015.​14215. eCollection 2015.PubMed
40.
Neveu B, Moreel X, Deschenes-Rompré, Bergeron A, LaRue H, Ayari C, Fradet Y, Fradet V. IL-8 secretion in primary cultures of prostate cells in associated with prostate cancer agressivness. Res rep urol. 2014 May 9;6:27–34. doi: 10.​2147/​RRU.​S58643. eCollection 2014
41.
Licastro F, Bertaccini A, Porcellini E, et al. Alpha 1 antichymotrypsin genotype is associated with increased risk of prostate carcinoma and PSA levels. Anticancer res. 2008;28:395–99.
42.
43.
Wang Q, Xia N, Li T, Xu Y, Zou Y, Zuo Y, Fan Q, Bawa-Khalfe T, Yeh ETH, Cheng J. SUMO-specific protease 1 promotes prostate cancer progression and metastasis. Oncogene. 2013;32:2493–8.CrossRefPubMed
44.
Fujita K, Shimomura M, Uemura M, Nakata W, Sato M, Nagahara A, Nakai Y, Takamatsu S, Miyoshi E, Nonomura N. Serum fucosylated haptoglobin as a novel prognostic biomarker predicting high-Gleason prostate cancer. Prostate. 2014;74(10):1052–8.CrossRefPubMed
45.
Savoy RM, Ghosh PM. Linking inflammation and neuroendocrine differentiation: the role of macrophage migration inhibitory factor-mediated signaling in prostate cancer. Endocr relat cancer. 2013;20(3):C1–4.CrossRefPubMed
46.
Tawadros T, Alonso F, Jichlinski P, Clarke N, Calandra T, Haefliger JA, Roger T. Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells. Endocr relat cancer. 2013;20(1):137–49.CrossRefPubMed
47.
48.
Taverna G, Giusti G, Seveso M, Hurle R, Colombo P, Stifter S, Grizzi F. Mast cells as a potential prognostic marker in prostate cancer. Dis markers. 2013;35(6):711–20.CrossRefPubMedPubMedCentral
49.
Xie H, Li C, Dang Q, Chang LS, Li L. Infiltrating mast cells increase prostate cancer chemotherapy and radiotherapy resistances via modulation of p38/p53/p21 and ATM signals. Oncotarget. 2016;7(2):1341–53.PubMed
50.
Taverna G, Pedretti E, Di Caro G, Borroni EM, Marchesi F, Grizzi F. Inflammation and prostate cancer: friends or foe? Inflamm res. 2015;64(5):275–86.CrossRefPubMed
51.
52.
Klink JC, Bañez LL, Gerber L, Lark A, Vollmer RT, Freedland SJ. Intratumoral inflammation is associated with more aggressive prostate cancer. World j urol. 2013;31(6):1497–503.CrossRefPubMed
53.
Santarpia L, Alfonsi L, Pasanisi F, et al. Predictive factors of survival in patients with peritonealcarcinomatosis on home parenteral nutrition. Nutrition. 2006;22:355–60.CrossRefPubMed
54.
Koie T, Ohyama C, Hatakeyama S, Imai A, Yoneyama T, Hashimoto Y, Yoneyama T, Tobisawa Y, Hosogoe S, Yamamoto H, Kitayama M, Hirota K. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy. Int j clin oncol. 2016;21(2):379–83.CrossRefPubMed
55.
Shafique K, Proctor MJ, Mcmillan DC, Qureshi K, Leung H, Morrison DS. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow inflammation outcome study. Prostate cancer prostatic dis. 2012;15(2):195–201.CrossRefPubMed
56.
Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, Foulis AK, Horgan PG, Mcmillan DC. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study. Eur j cancer. 2011;47(17):2633–41.CrossRefPubMed
57.
McArdle PA, Qayyum T, McMillan DC. Systemic inflammation response and survival in patients with localized prostate cancer. Urol Int. 2010;85(4):482-9.
58.
Langsenlehner T, Thurner EM, Krenn-Pilko S, Langsenlehner U, Stojakovic T, Gerger A, Pichler M. Vaidation of the neutrophil-to-lymphocyte ration as a prognostic factor in a cohort of European prostate cancer patients. World j urol. 2015;33:1661–7.CrossRefPubMed
59.
Bahig H, Taussky D, Delouya G, Nadiri A, Gagnon-Jacques A, Bodson-Clermont P, Soulieres D. Neutrophil count is associated with survival in localized prostate cancer. BMC cancer. 2015;15:594.CrossRefPubMedPubMedCentral
60.
Langsenlehner T, Pichler M, Thurner EM, Krenn-Pilko S, Stojakovic T, Gerger A, Langsenlehner U. Evaluation of the platelet-to-lymphocyte ratio as a prognostic indicator in a European cohort of patients with prostate cancer treated with radiotherapy. Urol oncol. 2015;33(5):e9–e16.CrossRef
61.
Schoenfeld JD, Margalit DN, Kasperzyk JL, Shui IM, Rider JR, Epstein MM, Meisner A, Kenfield SA, Martin NE, Nguyen PL, Kantoff PW, Giovannucci EL, Stampfer MJ, Mucci LA. A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. Clin cancer res. 2013;19(6):1612–9.CrossRefPubMedPubMedCentral
62.
Thurner EM, Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, Kapp KS, Langsenlehner T. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy. Eur j cancer. 2015;51(5):610–9.CrossRefPubMed
63.
Green MM, Hiley CT, Shanks JH, Bottomley IC, West CM, Cowan RA. Stratford. Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int j radiat oncol biol phys. 2007;67(1):84–90.CrossRefPubMed
64.
Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, Slawin KM. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J clin oncol. 2004;22(9):1655–63.CrossRefPubMed
65.
Nguyen DP, Li J, Yadav SS, Tewari AK. Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer. BJU int. 2014;114(2):168–76.CrossRefPubMed
66.
Sharma J, Gray KP, Harshman LC, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ. Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate. 2014;74(8):820–8.CrossRefPubMed
67.
Templeton AJ, Pezaro C, Omlin A, Mcnamara MG, Leibowitz-Amit R, Vera-Badillo FE, Attard G, de Bono JS, Tannock IF, Amir E. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer. 2014;120(21):3346–52.CrossRefPubMed
68.
Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, Bahl A, Shen L, Su Z, Sartor O, de Bono JS. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann oncol. 2015;26(4):750–5.CrossRefPubMed
69.
van Soest RJ, Templeton AJ, Vera-Badillo FE, Mercier F, Sonpavde G, Amir E, Tombal B, Rosenthal M, Eisenberger MA, Tannock IF, de Wit R. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann oncol. 2015;26(4):743–9.CrossRefPubMed
70.
Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ, Vardy JL, Templeton AJ, Wang SL, Paolini J, Chen I, Chow-Maneval E, Lechuga M, Smith MR, Michaelson MD. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer. Clin genitourin cancer. 2014;12:317–24.CrossRefPubMed
71.
Liao SG, Cheng HH, Lei Y. C-reactive protein is a prognostic marker for patients with castration-resistant prostate cancer. Oncol res treat. 2016;39(5):266–71.CrossRefPubMed
72.
Linton A, Pond G, Clarke S, Vardy J, Galsky M, Sonpavde G. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin genitourin cancer. 2013;11(4):423–30.CrossRefPubMed
73.
Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atenafu EG, Keizman D, Vera-Badillo F, Seah JA, Attard G, Knox JJ, Sridhar SS, Tannock IF, Del Bono JS, Joshua AM. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration resistant prostate cancer. Ann oncol. 2014;25:657–62.CrossRefPubMedPubMedCentral
74.
Metadata
Title
Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review
Authors
Alessandro Sciarra
Alessandro Gentilucci
Stefano Salciccia
Federico Pierella
Flavio Del Bianco
Vincenzo Gentile
Ida Silvestri
Susanna Cattarino
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2016
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/s12950-016-0143-2

Other articles of this Issue 1/2016

Journal of Inflammation 1/2016 Go to the issue

Research

Circulating adipokine levels and prognostic value in septic patients

Research

Electric stimulation of the vagus nerve reduced mouse neuroinflammation induced by lipopolysaccharide

Research

Interleukin-1beta-induced reduction of tissue water diffusion in the juvenile rat brain on ADC MRI is not associated with 31P MRS-detectable energy failure

Research

Effects of CpG Oligodeoxynucleotide 1826 on transforming growth factor-beta 1 and radiation-induced pulmonary fibrosis in mice

Research

The association between blood glucose levels and matrix-metalloproteinase-9 in early severe sepsis and septic shock

Short report

Nur77-mediated TRAF6 signalling protects against LPS-induced sepsis in mice

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits